Table 2 Clinical trials including agents targeting the immune cells of the TME in B cell lymphomas
From: Insights into the tumor microenvironment of B cell lymphoma
Immune cells | Identifier | Study | Phase | Target | Agent |
|---|---|---|---|---|---|
Tfh cells | NCT02376699 | A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies | I | CD40 | SEA-CD40 |
Treg cells | NCT04855253 | Phase I/II Trial Using E7777 to Enhance Regulatory T-cell Depletion Prior to Tisagenlecleucel (Kymriah) Therapy for Relapsed/Refractory DLBCL | I/II | IL-2 | E7777 |
NCT01919619 | A Pilot Study of Lenalidomide Alternating with Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation | II | CTLA-4 | Ipilimumab | |
NCT04544059 | Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in DLBCL | II | CD28 | Lenalidomide | |
NCT05429 | A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants with Relapsed or Refractory DLBCL | III | CD28 | Lenalidomide | |
NCT04432402 | Efficacy and Safety of Lenalidomide in Combination with R-GemOx in First-line treatment of Elderly DLBCL | N/A | CD28 | Lenalidomide | |
NCT04432402 | Duvelisib Exposure to Enhance Immune Profiles of T cells in Patients with DLBCL (DEEP T CELLS) | I | PI3K | Duvelisib | |
NCT04849351 | A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients with Relapsed/Refractory MZL and FL | II | PI3K | Amdizalisib, HMPL-689 | |
NCT03314922 | A Phase 1b, Open-Label, Dose-Escalation Study for the Safety, Tolerability, and Pharmacokinetics of INCB050465 in Japanese Subjects with Previously Treated B-cell lymphoma (CITADEL-111) | I | PI3K | Parsaclisib | |
NCT03919175 | A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients with FL and MZL | II | PI3K | Umbralisib | |
NCT02367040 | A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination with Rituximab in Patients with Relapsed iNHL – CHRONOS-3 | III | PI3K | Copanlisib (Aliqopa, BAY80-6946) | |
NCT03884998 | A Phase 1 study of PI3Kα,δ Inhibitor Copanlisib in Combination with PD-1 Antagonist Nivolumab in Patients with Transformed CLL (Richter’s Transformation) or NHL | I | PI3K | Copanlisib (Aliqopa, BAY80-6946) | |
Effector CD8+ T cells | NCT04566978 | A Pilot Study of 89Zr-DFO-REGN3767 Anti LAG-3 Antibody Positron Emission Tomography in Patients with Relapsed/Refractory DLBCL | I | LAG3 | 89Zr-DFO-REGN3767 |
NCT05039658 | A Phase Ib, Open Label, Randomized, Multicenter Study of the Efficacy and Safety of IBI110 Single Agent and in Combination with Sintilimab for Patients with Relapsed or Refractory DLBCL | Ib | LAG3 | IBI110 | |
NCT02061761 | A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (Relatlimab, BMS-968016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) In relapsed or Refractory B-cell Malignancies | I/IIA | LAG3 | Relatlimab, BMS-896016 | |
NCT05255601 | A Phase I/II study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical HL and NHL | I/II | LAG3 | Relatlimab, BMS-896016 | |
NCT04767308 | A Single-center, Single-arm Exploratory Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-CD5 Chimeric Antigen Receptor T cells (CT125A Cells) for the Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | I | CD5 | CD125A cells | |
NCT01919619 | A Pilot Study of Lenalidomide Alternating with Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation | II | CTLA4 | Ipilimumab | |
TAMs | NCT03530683 | A Phase1a/1b Dose-Escalation and Expansion Trial of TTI-622 in patients with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma | I | SIRPα | TTI-622 (SIRPα-IgG4 Fc) |
NCT05507541 | Randomized Phase 2 Study with Safety Run-In of PD-1 Inhibitor and IgG4 SIRPα-Fc Fusion Protein (TTI-622) and PD-1 Inhibitor and IgG1 SIRPα-Fc Fusion Protein (TTI-621) in Relapsed DLBCL | II | SIRPα | TTI-622 (SIRPα-IgG4 Fc) | |
NCT02953509 | A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell NHL | Ib/II | CD47 | Hu5F9-G4 | |
NCT05626322 | A Phase 1b/2 Study of PF-07901801, a CD47 Blocking Agent, with Tafasitamab and Lenalidomide for Participants with Relapsed/Refractory DLBCL Not Eligible for Stem Cell Transplantation | II | CD47 | PF-07901801 | |
NCT05025800 | A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients with Indolent and Aggressive B-cell NHL | I/II | CD47 | ALX148 | |
NCT04806035 | A Phase 1b Multi-cohort Study of TG-1801 Alone in Combination with Ublituximab in Subjects with B-cell Lymphoma or CLL | I | CD47 | TG-1801 | |
MDSCs | NCT03711604 | An Open Label, Compassionate Use Study of Tenalisib (RP6530) in Patients Currently Receiving Treatment on Tenalisib Trials in Hematological Malignancies | I/II | PI3K δ/γ | Tenalisib (RP6530) |
NCT02916979 | A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators’ Expression in Allogeneic Stem cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine | I |  | Myeloablative Busulfan and Fludarabine | |
CAFs | NCT03155620 | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice Screening Protocol) | II | FGFR | JNJ-42756493 |
NCT02465060 | Molecular Analysis for Therapy Choice (MATCH) | II | FGFR | JNJ-42756493 | |
NK cells | NCT03056339 | Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction with Lymphodepleting Chemotherapy in Patients with Relapsed/Refractory B-Lymphoid Malignancies | I/II | CD19 | iC9/CAR.19/IL15-Transfuced CB-NK Cells |
NCT04052061 | Open-Label, Phase I Study of CD19 t-haNK in Subjects with DLBCL who have Received 2 or More Lines of Therapy and Are Ineligible for Transplant | I | CD19 | CD19 t-haNK | |
NCT04074746 | Bispecific NK Engager AFM13 Combined with NK Cells for Patients with Recurrent of Refractory CD30 Positive HL or NHL | I/II | CD30 | AFM13 | |
NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination with ALT-803 | I | IL-15 | ALT-803 | |
NCT04609579 | A Phase 1 Open-label of Study SNX281 Given as Monotherapy and in Combination with a Checkpoint Inhibitor in Subjects with Advanced Solid Tumors and Lymphoma | I | STING protein | SNX281 | |
NCT02727803 | Personalized NK Cell Therapy in CBT | II | Â | Allogeneic Natural killer Cell Line NK-92 | |
NCT05472558 | Clinical Study of Cord Blood-Derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | I | CD19 | CAR-NK cells | |
NCT04639739 | Anti-CD19 CAR-NK Cell Therapy for Relapsed or Refractory B-cell NHL: a Multi-center, Uncontrolled Trial | I | CD19 | CAR-NK cells | |
NCT04796688 | Safety and Efficacy of Universal Chimeric Antigen Receptor-modified AT19 Cells in Patients with CD19+ Relapsed/Refractory Hematological Malignancies: a Single-center, Open-label, Single-arm Clinical Study | I | CD19 | CAR-NK cells | |
NCT05379647 | QN-019a as a Monotherapy and in Combination with Anti-CD20 Monoclonal Antibodies in Subjects with B-cell Malignancies | I | CD19 | QN-019a, CAR-NK cells |